FDA Brief

Warning letters Drugs

FDA warning letter to

NV Nutrition, LLC

High riskIssued Dec 1, 2021Posted Dec 7, 2021Center for Drug Evaluation and Research | CDER

FDA warned NV Nutrition that its inhalable vaporizer and diffuser products are drugs sold without FDA approval and promoted with disease claims.

What happened

In October 2021, FDA reviewed NV Nutrition's websites, social media pages, and product packaging and found claims that the vaporizer and diffuser products treat or manage conditions such as insomnia, anxiety, hangovers, and immune problems. FDA said the products are intended for inhalation, not ingestion, so they do not meet the dietary supplement definition, and no approved drug applications are in effect.

What FDA found

  1. The products are new drugs because they are not generally recognized as safe and effective for their claimed uses and no approved applications are in effect.

    FD&C Act sections 201(p), 505(a), and 301(d), 21 U.S.C. 321(p), 355(a), and 331(d)
  2. Website, social media, and packaging claims show the products are intended to cure, mitigate, treat, or prevent disease or affect body structure or function, making them drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  3. The products carry Supplement Facts panels but are intended for inhalation, not ingestion, so they are not dietary supplements.

    FD&C Act section 201(ff)(2)(A)(i), 21 U.S.C. 321(ff)(2)(A)(i)
  4. The products are introduced or delivered for introduction into interstate commerce without an approved new drug application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA tells the company to notify it in writing within 15 working days of receipt of the letter with the specific steps taken to address the violations, an explanation of each step, and related documentation. If the company believes it is not violating the law, it must include its reasoning and supporting information; if it cannot complete the work in time, it must state why and when it will.

Who should pay attention

  • companies selling inhalable supplements or vaporizer/diffuser products
  • e-commerce brands that make disease or structure/function claims
  • contract manufacturers and packagers of inhalable wellness products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk